Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

[1]  K. Carlström,et al.  Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens , 1995, Calcified Tissue International.

[2]  C. Tyrrell,et al.  Osteoporosis occurring in two patients receiving LHRH analogs for carcinoma of the prostate , 1994, Calcified Tissue International.

[3]  P. Kantoff,et al.  Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. , 2001, The New England journal of medicine.

[4]  M. Parmar,et al.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[5]  M. Terris,et al.  Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. , 2001, Urology.

[6]  L. Dogliotti,et al.  Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. , 2000, The Journal of urology.

[7]  A. Furuta,et al.  Incidence of bone fracture in patients receiving luteinizing hormone‐releasing hormone agonists for prostate cancer , 2000, BJU international.

[8]  E. Orwoll,et al.  Alendronate for the treatment of osteoporosis in men. , 2000, The New England journal of medicine.

[9]  S. Cerutti,et al.  Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment. , 2000, Oncology reports.

[10]  H. Herr,et al.  Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. , 2000, The Journal of urology.

[11]  D. Kiel,et al.  Risk Factors for Longitudinal Bone Loss in Elderly Men and Women: The Framingham Osteoporosis Study , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  D. Ferguson,et al.  Progressive osteoporosis during androgen deprivation therapy for prostate cancer. , 2000, The Journal of urology.

[13]  R. Stege.  Potential side‐effects of endocrine treatment of long duration in prostate cancer , 2000, The Prostate. Supplement.

[14]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[15]  John T. Wei,et al.  Androgen deprivation therapy for prostate cancer results in significant loss of bone density. , 1999, Urology.

[16]  J. Sibilia,et al.  Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. , 1999, The Journal of urology.

[17]  T. Diamond,et al.  The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma , 1998, Cancer.

[18]  M. Barry,et al.  Androgen deprivation therapy for asymptomatic advanced prostate cancer in the prostate specific antigen era: a national survey of urologist beliefs and practices. , 1998, The Journal of urology.

[19]  N. Mauras,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Testosterone Deficiency in Young Men: Marked Alterations in Whole Body Protein Kinetics, Strength, and Adiposity* , 2022 .

[20]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[21]  H. Daniell.  Osteoporosis after orchiectomy for prostate cancer. , 1997, The Journal of urology.

[22]  S. Graham,et al.  Bone fractures associated with luteinizing hormone‐releasing hormone agonists used in the treatment of prostate carcinoma , 1997, Cancer.

[23]  P. Ross.  Osteoporosis. Frequency, consequences, and risk factors. , 1996, Archives of internal medicine.

[24]  T. Diamond,et al.  Osteoporosis as a complication of orchiectomy in 2 elderly men with prostatic cancer. , 1995, The Journal of urology.

[25]  E. Seeman.  Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities. , 1993, The American journal of medicine.

[26]  C. Rosen,et al.  Validation of a quantitative food frequency questionnaire for rapid assessment of dietary calcium intake. , 1989, Journal of the American Dietetic Association.

[27]  D. Baylink,et al.  Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. , 1989, The Journal of clinical endocrinology and metabolism.

[28]  D. Wolfe,et al.  Nonparametric Statistical Methods. , 1974 .